Clinical Trial Update: Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene [Phase 2]

View source ↗

Summary

Update on a Phase 2 trial of crenolanib in patients with advanced gastrointestinal stromal tumor with D842-related PDGFRA mutations. The study status is complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Crenolanib (Crenolanib)

Snippet

Sponsor: Arog Pharmaceuticals, Inc. | Conditions: D842-related Mutant GIST | Phase 2 | Status: COMPLETED